SCHEMBL1284027

SCHEMBL1284027

Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)CCl)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.81
CDK8 P49336 3/20 0.70
MAPK14 Q16539 6/20 0.67
MAPK13 O15264 3/20 0.63
MAPK12 P53778 3/20 0.63
MAPK11 Q15759 3/20 0.63
ALDH1A1 P00352 2/20 0.62
LMNA P02545 2/20 0.62
HTT P42858 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
MEN1 O00255 1/20 0.62
POLB P06746 1/20 0.62
MAPT P10636 1/20 0.62
KMT2A Q03164 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
CCNC P24863 1/20 0.60
PTK2 Q05397 5/20 0.58
CYP2D6 P10635 2/20 0.58
CYP2C9 P11712 2/20 0.58
DDR2 Q16832 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1600309 0.86 CDK8 (0.82) JAK2CDK8MAPK14MAPK13MAPK12
SCHEMBL26936743 0.84 CDK8 (0.66) JAK2CDK8MAPK14MAPK13MAPK12
SCHEMBL9967321 0.84 CDK8 (0.78) JAK2CDK8MAPK14MAPK13MAPK12
SCHEMBL13199966 0.83 MAPK14 (0.63) JAK2CDK8MAPK14MAPK13MAPK12
SCHEMBL1600918 0.83 MAPK14 (0.68) JAK2CDK8MAPK14MAPK13MAPK12
SCHEMBL18744685 0.83 CDK8 (0.76) JAK2CDK8MAPK14MAPK13MAPK12
SCHEMBL15946922 0.83 CDK8 (0.76) JAK2CDK8MAPK14MAPK13MAPK12
SCHEMBL19303194 0.83 CDK8 (1.00) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL1600736 0.82 MAPK14 (0.64) JAK2CDK8MAPK14MAPK13MAPK12
SCHEMBL1600182 0.82 CDK8 (0.60) JAK2CDK8MAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8557797-B2 Triazolopyridine derivatives and their therapeutic use CHIESI FARMACEUTICI S.P.A. (IT) 2013-10-15 US disclosed
US-8557797-B2 Triazolopyridine derivatives and their therapeutic use CHIESI FARMACEUTICI S.P.A. (IT) 2013-10-15 US disclosed
US-8557797-B2 Triazolopyridine derivatives and their therapeutic use CHIESI FARMACEUTICI S.P.A. (IT) 2013-10-15 US disclosed
US-20120088763-A1 TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE CHIESI FARMACEUTICI S.P.A. (IT) 2012-04-12 US disclosed
US-20120088763-A1 TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE CHIESI FARMACEUTICI S.P.A. (IT) 2012-04-12 US disclosed
US-20120088763-A1 TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE CHIESI FARMACEUTICI S.P.A. (IT) 2012-04-12 US disclosed
WO-2010094956-A1 TRIAZOLOPYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED. (GB) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088763-A1 TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE CNKSR1, MOK, MAPK1 JAK2 46/4885CDK8 324/4885MAPK14 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.